Cibisatamab Antibody

Cibisatamab is a bispecific T-cell engager targeting CEA on tumor cells and CD3 on T-cells, inducing T-cell-mediated cytotoxicity against CEA-positive cancers. It is utilized in preclinical research for solid tumors like colorectal cancer, supporting both in vitro cell-based assays and in vivo xenograft studies to investigate its therapeutic potential.